febuxostat has been researched along with methotrexate in 6 studies
| Studies (febuxostat) | Trials (febuxostat) | Recent Studies (post-2010) (febuxostat) | Studies (methotrexate) | Trials (methotrexate) | Recent Studies (post-2010) (methotrexate) |
|---|---|---|---|---|---|
| 818 | 133 | 710 | 41,593 | 5,666 | 11,969 |
| Protein | Taxonomy | febuxostat (IC50) | methotrexate (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.8 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 0.211 | |
| Toll-like receptor 4 | Homo sapiens (human) | 1.04 | |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | 0.08 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0522 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.0331 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0348 | |
| Dihydrofolate reductase | Gallus gallus (chicken) | 0.0545 | |
| Dihydrofolate reductase | Enterococcus faecium | 0.0014 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0138 | |
| Thymidylate synthase | Homo sapiens (human) | 0.343 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0147 | |
| Thymidylate synthase | Escherichia coli K-12 | 0.0181 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1529 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.084 | |
| Folate receptor beta | Homo sapiens (human) | 0.1585 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0011 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.0012 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2263 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0717 | |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | 0.0014 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.01 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.01 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Reduced folate transporter | Homo sapiens (human) | 0.012 | |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | 0.0174 | |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | 3.2 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0547 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.11 | |
| Dihydrofolate reductase | Bacillus anthracis | 0.0136 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0047 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.1207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Hiramatsu, SI; Ikemura, K; Iwamoto, T; Katayama, N; Nakatani, Y; Okuda, M; Shinogi, Y; Tawara, I | 1 |
| Abd Algaleel, WA; Hussein, GHA; Khalil, HMA; Zaki, SM | 1 |
| Ishida, S; Ishizawa, K; Kanda, M; Mitsuboshi, S; Niimura, T; Zamami, Y | 1 |
1 review(s) available for febuxostat and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for febuxostat and methotrexate
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Synergism; Febuxostat; Female; Gout Suppressants; Hematopoiesis; Humans; Kidney; Kidney Function Tests; Liver; Liver Function Tests; Male; Methotrexate; Middle Aged; Neoplasm Proteins | 2019 |
Febuxostat ameliorates methotrexate-induced lung damage.
Topics: Animals; Antioxidants; Febuxostat; Lung; Methotrexate; Oxidative Stress; Rats | 2021 |
Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat.
Topics: Allopurinol; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Febuxostat; Female; Gout Suppressants; Humans; Methotrexate; Middle Aged; Neoplasm Proteins | 2022 |